Skip Navigation
Print This Page
Share this page: More

Search Results

A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients with Platinum-Resistant Ovarian Cancer
Protocol Number:
Phase II
Deborah Armstrong
- To evaluate the efficacy of DNIB0600A compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer as determined by progression-free survival - To evaluate the efficacy of DNIB0600A compared with PLD in patients s assessed by overall survival
- recurrent platinum resistant ovarian cancer - maximum of 2 prior chemo regimens - No prior pegylated liposomal doxorubicin - Must have measurable disease - No known HIV, Hep C or Hep B - Good lab values and performance status
- Patients are randomized to receive either DNIB0600A on Day 1 of each 28 day cycle or pegylated liposomal doxorubicin on Day 1 of each 28 day cycle. - This is an outpatient treament that can continue until disease progression or side effect prohibit further therapy.
Last Update
12/25/2014 04:03 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.